Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Fair Value

Margin Of Safety %

Put/Call OI Ratio

0.06

Float Short​ %​

5.96

EPS 1 Diff

0.01

EPS Year Diff

0.28

Ticker: CUE




21 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2024-09-06CUE0.59180.05999.991990
2024-09-09CUE0.5690.05999.991990
2024-09-10CUE0.5790.05999.991990
2024-09-11CUE0.59260.05999.991990
2024-09-12CUE0.58760.050.001991
2024-09-13CUE0.58680.050.002016
2024-09-16CUE0.56250.050.002016
2024-09-17CUE0.56620.050.002016
2024-09-18CUE0.55830.050.002016
2024-09-19CUE0.5650.050.502016
2024-09-20CUE0.5250.050.502016
2024-09-23CUE0.47470.05999.991927
2024-09-24CUE0.48460.040.001919
2024-09-25CUE0.46430.040.001920
2024-09-26CUE0.45020.040.001920
2024-09-27CUE0.66940.041.251941
2024-09-30CUE0.76010.060.062042
2024-10-01CUE0.7090.060.152120
2024-10-02CUE0.72990.060.032095
2024-10-03CUE0.82520.060.032119
2024-10-04CUE1.150.060.052146
DateSymbolLastP/C OIP/C VolTotal OI
21 items Current Page1 of 1




21 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2024-09-06CUE0.5920.8- -0.83
2024-09-09CUE0.5720.8- -0.83
2024-09-10CUE0.5720.8- -0.83
2024-09-11CUE0.5920.8- -0.83
2024-09-12CUE0.5620.8- -0.83
2024-09-13CUE0.5820.8- -0.83
2024-09-16CUE0.5620.8- -0.83
2024-09-17CUE0.5720.8- -0.83
2024-09-18CUE0.5620.8- -0.83
2024-09-19CUE0.5620.8- -0.83
2024-09-20CUE0.5220.8- -0.83
2024-09-23CUE0.4820.8- -0.83
2024-09-24CUE0.4820.8- -0.83
2024-09-25CUE0.4820.8- -0.83
2024-09-26CUE0.4520.8- -0.83
2024-09-27CUE0.6820.8- -0.83
2024-09-30CUE0.7620.8- -0.83
2024-10-01CUE0.7120.8- -0.83
2024-10-02CUE0.7420.8- -0.83
2024-10-03CUE0.8320.8- -0.83
2024-10-04CUE1.1520.8- -0.83
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
21 items Current Page1 of 1




21 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2024-09-06CUE0.00-6.787.59
2024-09-09CUE0.00-6.787.59
2024-09-10CUE0.00-6.787.59
2024-09-11CUE0.00-6.787.59
2024-09-12CUE0.00-6.787.11
2024-09-13CUE0.00-6.787.11
2024-09-16CUE0.00-6.787.11
2024-09-17CUE0.00-6.787.11
2024-09-18CUE0.00-6.787.11
2024-09-19CUE0.00-6.787.11
2024-09-20CUE0.00-6.787.11
2024-09-23CUE0.00-6.787.11
2024-09-24CUE0.00-6.787.11
2024-09-25CUE0.00-6.787.38
2024-09-26CUE0.00-6.787.38
2024-09-27CUE0.00-6.787.38
2024-09-30CUE0.00-6.787.38
2024-10-01CUE0.00-6.787.38
2024-10-02CUE0.00-6.787.38
2024-10-03CUE0.00-6.785.96
2024-10-04CUE0.00-6.785.96
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
21 items Current Page1 of 1

Last Quarter Act. EPS

-0.2

Avg. EPS Est. Current Quarter

-0.19

Avg. EPS Est. Next Quarter

-0.19

Insider Transactions

Institutional Transactions

-6.78

Beta

1.94

Average Sales Estimate Current Quarter

1

Average Sales Estimate Next Quarter

5

Fair Value (Academic)

Quality Score

18

Growth Score

38

Sentiment Score

88

Actual DrawDown %

96.4

Max Drawdown 5-Year %

-98.5

Target Price

3.5

P/E

Forward P/E

PEG

P/S

8.41

P/B

2.61

P/Free Cash Flow

EPS

-0.97

Average EPS Est. Cur. Y​

-0.83

EPS Next Y. (Est.)

-0.64

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-566.02

Relative Volume

13.87

Return on Equity vs Sector %

-238.8

Return on Equity vs Industry %

-259.9

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Cue Biopharma, Inc.
Sector: Healthcare
Industry: Biotechnology
Employees: 53
Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells directly within the patient's body. Its lead drug product candidate is CUE-101 for the treatment of human papilloma virus (HPV16+)-driven recurrent/metastatic head and neck cancer. The company is also developing CUE-102 targets Wilms' Tumor 1 protein in various cancers; CUE-103, a CUE-100 series drug product candidate; and Neo-STAT and RDI-STAT programs outside of oncology, including CUE-200, CUE-300, and CUE-400 series. It has collaboration agreements with LG Chem, Ltd. for the development of Immuno-STATs focused in the field of oncology; strategic collaboration and option agreement with Ono Pharmaceutical Co., Ltd. to advance CUE-401 for the treatment of autoimmune and inflammatory diseases; and license agreement with Albert Einstein College of Medicine. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.
stock quote shares CUE – Cue Biopharma Inc Stock Price stock today
news today CUE – Cue Biopharma Inc stock forecast ,stock prediction 2023 2024 2025
marketwatch CUE – Cue Biopharma Inc yahoo finance google finance
stock history CUE – Cue Biopharma Inc invest stock market
stock prices CUE premarket after hours
ticker CUE fair value insiders trading